May 15, 2024 · Metastatic castration-resistant prostate cancer (mCRPC) and its precursor, metastatic hormone sensitive prostate cancer (mHSPC), are advanced forms of the condition that don’t respond to initial treatments, such as surgery and hormone therapy, and have started to spread beyond the prostate.

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With CRPC, the cancer no longer completely responds to treatments that lower testosterone. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone.

Jun 19, 2024 · When the cancer keeps growing even though your testosterone production remains low, this is when you are likely to get a diagnosis of castration-resistant prostate cancer (CRPC)....

From conditions to treatments to surgical devices and more, we've put everything you need to know about urology in one convenient place. The Urology Care Foundation is a driving force in the discovery of new treatments, because we invest in the next generation of researchers.

We reviewed the current treatment options for mCRPC, with insights on new available therapeutic strategies. Chemotherapy with docetaxel or cabazitaxel (for patients progressing on docetaxel), as well as treatment with androgen receptor axis targeted therapies, and Radium-223 are well-established treatment options for patients with mCRPC.

Jul 19, 2023 · It’s a somewhat long and confusing name, but the term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland...

Metastatic castration resistant prostate cancer (mCRPC) Silke Gillessen, MD Medical Oncology Division of Cancer Sciences , University of Manchester and The Christie, Manchester,

Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation.

1 day ago · Key Takeaways. Talazoparib and enzalutamide combination reduces death risk by 20.4% in mCRPC patients, regardless of HRR status. The combination therapy offers survival benefits without increased ...

CRPC is defined as castrate serum testosterone levels (<50 ng/dL or 1.7 nmol/L) plus either biochemical or radiological progression, as specified in the European Association of Urology guidelines [5]. CRPC can take place in both non-metastatic and metastatic settings.